HUP9700661A2 - Alfa1-adrenoreceptor antagonisták felhasználása rák megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására - Google Patents

Alfa1-adrenoreceptor antagonisták felhasználása rák megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására

Info

Publication number
HUP9700661A2
HUP9700661A2 HU9700661A HUP9700661A HUP9700661A2 HU P9700661 A2 HUP9700661 A2 HU P9700661A2 HU 9700661 A HU9700661 A HU 9700661A HU P9700661 A HUP9700661 A HU P9700661A HU P9700661 A2 HUP9700661 A2 HU P9700661A2
Authority
HU
Hungary
Prior art keywords
production
profilacting
pharmaceuticals
alpha
treating cancer
Prior art date
Application number
HU9700661A
Other languages
English (en)
Inventor
Timothy C. Thompson
Michael G. Wyllie
Guang Yang
Original Assignee
Baylor College Of Medicine
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine, Pfizer Inc. filed Critical Baylor College Of Medicine
Publication of HU9700661D0 publication Critical patent/HU9700661D0/hu
Publication of HUP9700661A2 publication Critical patent/HUP9700661A2/hu
Publication of HUP9700661A3 publication Critical patent/HUP9700661A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Eljárás emlősök rákős betegségeinek kezelésére vagy megelőzésérealkalmas gyógyszerkészítmény előállítására, mely hatásős mennyiségűa1-adrenőreceptőr antagőnistát vagy gyógyászati szempőntbólalkalmazható savaddíciós sóját tartalmaz. Előnyös vegyületek aprazősin, a dőxazősin és ennek 5'- és 7'-hidrőxi metabőlitjai. ŕ
HU9700661A 1996-03-27 1997-03-26 Use of alpha-1-adrenoreceptor antagonists for the production of pharmaceuticals for profilacting and treating cancer HUP9700661A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1422896P 1996-03-27 1996-03-27

Publications (3)

Publication Number Publication Date
HU9700661D0 HU9700661D0 (en) 1997-05-28
HUP9700661A2 true HUP9700661A2 (hu) 1998-11-30
HUP9700661A3 HUP9700661A3 (en) 1999-06-28

Family

ID=21764236

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9700661A HUP9700661A3 (en) 1996-03-27 1997-03-26 Use of alpha-1-adrenoreceptor antagonists for the production of pharmaceuticals for profilacting and treating cancer

Country Status (16)

Country Link
US (1) US5935962A (hu)
EP (1) EP0799618B1 (hu)
JP (1) JPH10101579A (hu)
KR (1) KR970064607A (hu)
AT (1) ATE294582T1 (hu)
AU (1) AU733146B2 (hu)
CA (1) CA2201089A1 (hu)
DE (1) DE69733169T2 (hu)
DK (1) DK0799618T3 (hu)
ES (1) ES2242207T3 (hu)
HU (1) HUP9700661A3 (hu)
IL (2) IL120303A0 (hu)
MY (1) MY126321A (hu)
NZ (1) NZ314488A (hu)
TW (1) TW504386B (hu)
ZA (1) ZA972601B (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU769446C (en) * 1999-01-27 2007-09-20 France Telecom Method for proving the authenticity or integrity of a message by means of a public exponent equal to the power of two
AU2001285232A1 (en) * 2000-08-24 2002-03-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Alpha-difluoromethylornithine (dfmo) use in the human prostate
PT1293198E (pt) * 2001-09-14 2005-06-30 Kissei Pharmaceutical Co Lda Dispositivo de administracao transdermica para o tratamento de patologias do tracto urinario
WO2006052409A2 (en) * 2004-10-23 2006-05-18 Case Western Reserve University Peptide and small molecule agonists of epha and their uses
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
WO2009131196A1 (ja) * 2008-04-24 2009-10-29 武田薬品工業株式会社 置換ピロリジン誘導体およびその用途
CN104288768A (zh) 2010-06-30 2015-01-21 盖尔德马研究及发展公司 α2-肾上腺素能受体激动剂的用途
US9554988B2 (en) 2010-06-30 2017-01-31 Galderma Research & Development Method for preventing or treating skin tumor
US20120178757A1 (en) * 2010-12-09 2012-07-12 Nottingham University Hospitals Nhs Trust Method For The Prevention Of Cancer Metastasis
GR20200100456A (el) * 2020-08-03 2022-03-09 Inderes Ltd, Συνδυασμος φαρμακων και χρηση του στη θεραπεια του καρκινου

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent
ATE187069T1 (de) * 1992-04-01 1999-12-15 Pfizer Hydroxylierte metaboliten und derivate von doxazosin gegen atherosklerose
FR2694495B1 (fr) * 1992-08-05 1994-09-23 Synthelabo Préparation pharmaceutique transdermique contenant de l'alfuzosine.
US5578611A (en) * 1992-11-13 1996-11-26 Synaptic Pharmaceutical Corporation Use of α-1C specific compounds to treat benign prostatic hyperplasia
US5503843A (en) * 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents

Also Published As

Publication number Publication date
HU9700661D0 (en) 1997-05-28
MY126321A (en) 2006-09-29
KR970064607A (ko) 1997-10-13
IL120495A0 (en) 1997-07-13
ATE294582T1 (de) 2005-05-15
AU1656997A (en) 1997-10-02
TW504386B (en) 2002-10-01
ES2242207T3 (es) 2005-11-01
IL120495A (en) 2004-09-27
IL120303A0 (en) 1997-06-10
AU733146B2 (en) 2001-05-10
EP0799618B1 (en) 2005-05-04
EP0799618A3 (en) 1997-11-12
DE69733169T2 (de) 2006-01-19
US5935962A (en) 1999-08-10
HUP9700661A3 (en) 1999-06-28
NZ314488A (en) 2000-09-29
EP0799618A2 (en) 1997-10-08
ZA972601B (en) 1998-09-28
DK0799618T3 (da) 2005-05-30
DE69733169D1 (de) 2005-06-09
CA2201089A1 (en) 1997-09-27
JPH10101579A (ja) 1998-04-21

Similar Documents

Publication Publication Date Title
BG101118A (en) Therapeutical compounds
MY125821A (en) Pharmaceutical composition of topiramate
BR9714363A (pt) Derivados de pirazol substituìdos para o tratamento de doenças circulatórias cardìacas
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
HUP9903694A2 (hu) Rho kináz gátlót tartalmazó gyógyszerkészítmény
CY1112260T1 (el) Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης
BR9709915A (pt) Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
ITRM920412A1 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiego terapeutico.
EA200100154A1 (ru) Бензоциклогептены, способ их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR0114344A (pt) Retinóides para o tratamento de enfisema
IT9048261A0 (it) Composizione farmaceutica per il trattamento di disturbi respiratori e metodo per la sua applicazione.
HUP9700660A2 (hu) Alfa1-adrenoreceptor antagonisták felhasználása a prosztata jóindulatú hyperpláziájának megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
DK0998287T3 (da) Anvendelse af levobupivacain
EE9900162A (et) Rinnavähi vältimise meetod, farmatseutiline preparaat ja toode ning toimeaine kasutamine
HUP9700661A2 (hu) Alfa1-adrenoreceptor antagonisták felhasználása rák megelőzésére és kezelésére alkalmas gyógyszerkészítmények előállítására
HUP9900819A1 (hu) Biciklusos aromás vegyületek, alkalmazásuk a humán- és állatgyógyászatban és a kozmetikában
HUP9700806A2 (hu) Tianeptin-nátriumsó nyújtott felszabadulását biztosító, szájon át beadható mátrix tabletta és eljárás előállítására
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DE69916488D1 (de) Substituierte caprolactam-derivate, diese enthaltende pharmazeutische zubereitungen sowie ihre verwendung zur behandlung von tumoren
FR2725990B1 (fr) Derives hydrosolubles d'epipodophyllotoxine, leur procede de preparation, leur utilisation a titre de medicament, et leur utilisation destinee aux traitements anticancereux
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease